Clinical trial
Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients
NCT02177682 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT02177682 |
|---|---|
| Title | Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients |
| Official title | An Open-label, Dose Escalation, Phase I Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients. |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms, Haematologic |
| Intervention type | Drug |
| Interventions | Afuresertib |
| Enrollment | 9 |
| Start date | Aug 13, 2014 |
| Primary completion | Feb 9, 2017 |
| Completion | Aug 14, 2019 |
| First posted | Jun 30, 2014 |
| Last update posted | Aug 11, 2021 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: